GT Biopharma, Inc. (GTBP)
- Previous Close
3.5800 - Open
3.6700 - Bid --
- Ask --
- Day's Range
3.5800 - 3.7900 - 52 Week Range
3.5200 - 16.1100 - Volume
3,408 - Avg. Volume
13,608 - Market Cap (intraday)
5.18M - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
-- - EPS (TTM)
-5.5800 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
150.00
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
www.gtbiopharma.comRecent News: GTBP
Performance Overview: GTBP
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GTBP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GTBP
Valuation Measures
Market Cap
5.18M
Enterprise Value
-8.73M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.69
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
1.18
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-55.02%
Return on Equity (ttm)
-79.09%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-7.6M
Diluted EPS (ttm)
-5.5800
Balance Sheet and Cash Flow
Total Cash (mrq)
13.97M
Total Debt/Equity (mrq)
0.78%
Levered Free Cash Flow (ttm)
-4.7M